# An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal

> **NCT05225844** · PHASE2 · UNKNOWN · sponsor: **Harbin Medical University** · enrollment: 150 (estimated)

## Conditions studied

- Gastrointestinal Cancer
- Immunotherapy
- Targeted Therapy

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Apatinib Mesylate

## Key facts

- **NCT ID:** NCT05225844
- **Lead sponsor:** Harbin Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-01
- **Primary completion:** 2022-02-01
- **Final completion:** 2022-10-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2022-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05225844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05225844, "An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05225844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*